Cellectis S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
5,362.00
21,627.00
50,346.00
40,491.00
22,331.10
10,791.30
Cost of Goods Sold (COGS) incl. D&A
2,390.00
3,178.00
2,632.00
3,603.00
5,311.50
2,321.70
Gross Income
2,972.00
18,449.00
47,714.00
36,888.00
17,019.60
8,469.60
SG&A Expense
35,030.00
27,378.00
79,491.00
108,131.00
106,926.40
104,950.20
EBIT
-
7,433.00
30,777.00
71,243.00
89,906.80
96,480.60
Unusual Expense
1,865.00
518.00
249.00
-
-
-
Non Operating Income/Expense
3,783.00
6,569.00
4,157.00
2,547.00
10,652.20
9,209.60
Interest Expense
326.00
414.00
27.00
2,622.00
496.50
612.80
Pretax Income
30,594.00
1,480.00
25,412.00
69,847.00
99,305.40
82,131
Income Tax
3,755.00
3,330.00
5,039.00
9,071.00
7,382.50
7,256.60
Consolidated Net Income
26,839.00
1,850.00
20,373.00
60,776.00
91,922.90
74,874.40
Net Income
25,822.00
2,842.00
20,544.00
60,776.00
88,097.30
66,703.10
Net Income After Extraordinaries
3,758.00
5,664.00
20,544.00
60,776.00
88,097.30
66,703.10
Net Income Available to Common
55,402.00
2,115.00
20,544.00
60,776.00
88,097.30
66,703.10
EPS (Basic)
2.68
-
0.60
1.72
2.46
1.64
Basic Shares Outstanding
20,653.90
26,071.70
34,149.90
35,289.90
35,690.60
40,774.20
EPS (Diluted)
2.68
0.00
0.60
1.70
2.47
1.64
Diluted Shares Outstanding
20,653.90
26,192.70
34,522.90
35,811.80
35,690.60
40,774.20
EBITDA
30,655.00
6,088.00
29,032.00
69,245.00
86,918.20
94,465.80
Other Operating Expense
445.00
1,496.00
1,000.00
-
-
-
Non-Operating Interest Income
317.00
316.00
986.00
1,471.00
1,750.10
5,752.90
Minority Interest Expense
1,017.00
992.00
171.00
-
3,825.60
8,171.20

About Cellectis

View Profile
Address
8, rue de la Croix Jarry
Paris Ile-de-France 75013
France
Employees -
Website http://www.cellectis.com
Updated 07/08/2019
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases.